524322
KABRADG
Start SIP
Invest Now
Start SIP in KABRADG
Performance
- Low
- ₹27
- High
- ₹29
- 52 Week Low
- ₹10
- 52 Week High
- ₹33
- Open Price₹28
- Previous Close₹28
- Volume68,643
- 50 DMA₹26.99
- 100 DMA₹24.05
- 200 DMA₹19.52
Investment Returns
- Over 1 Month + 5.54%
- Over 3 Month + 43.36%
- Over 6 Month + 36.47%
- Over 1 Year + 182.31%
Smart Investing Starts Here Start SIP with Kabra Drugs for Steady Growth!
Kabra Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 56.4
- PEG Ratio
- 0.3
- Market Cap Cr
- 67
- P/B Ratio
- 2.6
- Average True Range
- 1.72
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 0.46
- RSI
- 47.13
- MFI
- 58.92
Kabra Drugs Financials
Kabra Drugs Technicals
EMA & SMA
Current Price
₹28.40
+
0.62
(2.23%)
- Bearish Moving Average 4
- Bullish Moving Average 12
- 20 Day
- ₹28.49
- 50 Day
- ₹26.99
- 100 Day
- ₹24.05
- 200 Day
- ₹19.52
Resistance and Support
27.87
- R3 31.11
- R2 30.04
- R1 28.94
- S1 26.77
- S2 25.70
- S3 24.60
Kabra Drugs Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-28 | Others | Inter alia, To sign an agreement with MR FRANCHISE to appoint around 200 channel partner throughout the Country for expansion. |
| 2025-11-13 | Quarterly Results | |
| 2025-10-08 | Others | Inter-aliam to consider 1.Approve the final draft of the Share Purchase Agreement (SPA) in relation to the acquisition of AMR PHARMA INDIA PRIVATE LIMITED. 2. Other business matters. |
| 2025-09-02 | Others | Inter-alia, to consider 1. Directors Report and Corporate Governance Report for the financial year 2024 -25. 2. Draft Notice calling the AGM. 3. Other business matters. |
| 2025-08-14 | Quarterly Results |
Kabra Drugs F&O
About Kabra Drugs
- NSE Symbol
- KABRADG
- BSE Symbol
- 524322
- Managing Director
- Mr. N Aravind
- ISIN
- INE323K01017
Similar Stocks to Kabra Drugs
Kabra Drugs FAQs
Kabra Drugs share price is ₹28 As on 19 January, 2026 | 17:56
The Market Cap of Kabra Drugs is ₹67.3 Cr As on 19 January, 2026 | 17:56
The P/E ratio of Kabra Drugs is 56.4 As on 19 January, 2026 | 17:56
The PB ratio of Kabra Drugs is 2.6 As on 19 January, 2026 | 17:56
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.